Literature DB >> 15122799

Variations in the serum concentrations of soluble Fas and soluble Fas ligand in Vietnamese patients infected with hepatitis B virus.

Le H Song1, Vu Q Binh, Dinh N Duy, Thomas C Bock, Peter G Kremsner, Adrian J F Luty, Elie Mavoungou.   

Abstract

Earlier studies of both chronic hepatitis B and C virus (HBV and HCV) patients have shown a strong correlation between the soluble membrane Fas (sFas) and Fas protein expression on hepatocytes. The serum concentrations of sFas and soluble Fas ligand (sFasL) was examined in both healthy and HBV-infected Vietnamese patients to determine their relationship with the outcome of HBV infection. Patients with chronic rather than acute HBV had significantly higher amounts of sFas and sFasL, whilst the highest concentrations of both molecules were detected in those with malignant forms of HBV infection. sFas and sFasL concentrations tended to increase with a profile that paralleled the progression from asymptomatic to acute through chronic to malignant states, most markedly in the case of sFas. The sFas:sFasL ratio highlighted the relative predominance of sFas in those with acute and chronic HBV compared with asymptomatic or severe forms. In patients with hepatocellular carcinoma (HCC) a significant correlation was also observed between sFasL and alpha-feto protein (AFP) levels. The results indicate that sFas and to a lesser extent sFasL levels are to some degree associated with clinical progression in HBV infection. Copyright 2004 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15122799     DOI: 10.1002/jmv.20082

Source DB:  PubMed          Journal:  J Med Virol        ISSN: 0146-6615            Impact factor:   2.327


  9 in total

1.  Serum levels of soluble Fas, nitric oxide and cytokines in acute decompensated cirrhotic patients.

Authors:  Christoph Elsing; Sabine Harenberg; Wolfgang Stremmel; Thomas Herrmann
Journal:  World J Gastroenterol       Date:  2007-01-21       Impact factor: 5.742

Review 2.  Hepatitis B virus e antigen and viral persistence.

Authors:  Kuen-Nan Tsai; Jing-Hsiung James Ou
Journal:  Curr Opin Virol       Date:  2021-10-28       Impact factor: 7.090

3.  Development of an accurate index for predicting outcomes of patients with acute liver failure.

Authors:  Anna Rutherford; Lindsay Y King; Linda S Hynan; Chetan Vedvyas; Wenyu Lin; William M Lee; Raymond T Chung
Journal:  Gastroenterology       Date:  2012-08-08       Impact factor: 22.682

Review 4.  Cellular and molecular mechanisms of liver injury.

Authors:  Harmeet Malhi; Gregory J Gores
Journal:  Gastroenterology       Date:  2008-05       Impact factor: 22.682

Review 5.  The Receptor Interacting Protein Kinases in the Liver.

Authors:  Lily Dara
Journal:  Semin Liver Dis       Date:  2018-02-22       Impact factor: 6.115

6.  High prevalence and significance of hepatitis D virus infection among treatment-naïve HBsAg-positive patients in Northern Vietnam.

Authors:  Bui Tien Sy; Boris A Ratsch; Nguyen Linh Toan; Le Huu Song; Christian Wollboldt; Agnes Bryniok; Hung Minh Nguyen; Hoang Van Luong; Thirumalaisamy P Velavan; Heiner Wedemeyer; Peter G Kremsner; C-Thomas Bock
Journal:  PLoS One       Date:  2013-10-18       Impact factor: 3.240

7.  Soluble MICB protein levels and platelet counts during hepatitis B virus infection and response to hepatocellular carcinoma treatment.

Authors:  Hoang Van Tong; Le Huu Song; Nghiem Xuan Hoan; Bui Khac Cuong; Bui Tien Sy; Ho Anh Son; Do Quyet; Vu Quoc Binh; Peter G Kremsner; Claus Thomas Bock; Thirumalaisamy P Velavan; Nguyen Linh Toan
Journal:  BMC Infect Dis       Date:  2015-01-23       Impact factor: 3.090

Review 8.  Cell Death in Liver Diseases: A Review.

Authors:  Layla Shojaie; Andrea Iorga; Lily Dara
Journal:  Int J Mol Sci       Date:  2020-12-18       Impact factor: 5.923

9.  Knowledge-based identification of soluble biomarkers: hepatic fibrosis in NAFLD as an example.

Authors:  Sandra Page; Aybike Birerdinc; Michael Estep; Maria Stepanova; Arian Afendy; Emanuel Petricoin; Zobair Younossi; Vikas Chandhoke; Ancha Baranova
Journal:  PLoS One       Date:  2013-02-06       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.